Suggestions
Idioma
metricas
Publish in this journal
Guide for authors
Searcher
Journal Information
Vol. 61. Issue 4.
Pages 263-332 (October - December 2026)
Cite
Cite
Share
Download PDF
More article options
Visits
1857
Vol. 61. Issue 4.
Pages 263-332 (October - December 2026)
Original article
The prognostic impact of non-progression in cardiac resynchronization therapy
El impacto pronóstico de la ausencia de progresión en la terapia de resincronización cardiaca
Visits
1857
Marta Catarina Bernardo
Corresponding author
mcrbernardo@chtmad.min-saude.pt

Corresponding author.
, Isabel Martins Moreira, Luís Azevedo, José Pedro Guimarães, Sílvia Leão, Renato Margato, Paulo Fontes, Sofia Silva Carvalho, José Ilídio Moreira
Departmento de Cardiologia, Unidade Local de Saúde Trás-os-Montes e Alto-Douro, Lordelo, Vila Real, Portugal
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Introduction and objectives

Among patients who do not demonstrate an echocardiographic response to cardiac resynchronization therapy (CRT), a subgroup with minimal change in remodeling parameters has been identified. Our objective is to evaluate the long-term outcomes of CRT recipients stratified by echocardiographic response.

Methods

We conducted a retrospective study of patients with left ventricular ejection fraction (LVEF) ≤35% who underwent CRT implantation between 2017 and 2024 and had a follow-up echocardiogram 6–12 months post-procedure. Patients were classified as: progressors (LVEF or left ventricular end-systolic volume [LVESV]<0%), non-progressors (LVEF=0–10% or LVESV=0–15%), and responders (LVEF ≥10% or LVESV ≥15%). The primary endpoint was a composite of all-cause death or heart failure hospitalization.

Results

We included 132 patients (68% males, median age 72 years), mean LVEF of 27% (±5.0). Overall, 15.2% were progressors, 9.1% non-progressors, and 75.8% responders. Ischemic aetiology was more common in progressors and non-progressors (26% responders, 42% non-progressors, 60% progressors; P=.010). During a mean follow up of 39±24 months, the primary endpoint occurred in 30.5% of patients, with significantly lower rates in responders (23.2%) compared with non-progressors (58.3%) and progressors (50.0%) (P<.005). In multivariate analysis, non-progressors had outcomes comparable to progressors (P=.76) but significantly worse than responders (HR=4.01).

Conclusions

In our population, non-progressors demonstrated similar outcomes to non-responders, underscoring the role of positive remodelling beyond stabilization and highlighting the need to optimize the echocardiographic response to CRT.

Keywords:
Cardiac resynchronization therapy
Heart failure
Stabilization
Nonprogression
Resumen
Introducción y objetivos

Entre los pacientes que no muestran una respuesta ecocardiográfica al tratamiento de resincronización cardiaca (TRC), se ha identificado un subgrupo con cambios mínimos en los parámetros de remodelado. Nuestro objetivo es evaluar los resultados a largo plazo de los receptores de TRC estratificados según la respuesta ecocardiográfica.

Métodos

Estudio retrospectivo de pacientes con fracción de eyección (FEVI) ≤ 35% sometidos a implante de TRC entre 2017 y 2024 y a los que se les realizó una ecocardiografía de seguimiento entre 6 y 12 meses tras la intervención. Los pacientes se clasificaron en progresores (FEVI o volumen sistólico final del ventrículo izquierdo [VSFVI] <0%), no progresores (FEVI=0-10% o VSFVI=0-15%) y respondedores (FEVI ≥ 10% o VSFVI ≥ 15%). El objetivo principal fue una combinación de muerte por cualquier causa u hospitalización por insuficiencia cardiaca.

Resultados

Se incluyó a 132 pacientes (68% varones, mediana de edad 72 años), con una FEVI media del 27% (± 5,0). El 15,2% fueron progresores, el 9,1% no progresores y el 75,8% respondedores. La etiología isquémica fue más frecuente en los progresores y los no progresores (26% de los respondedores, 42% de los no progresores, 60% de los progresores; p=0,010). Durante el seguimiento medio de 39±24 meses, el objetivo principal se produjo en el 30,5% de los pacientes, con tasas significativamente más bajas en los respondedores (23,2%) comparados con los no progresores (58,3%) y los progresores (50,0%) (p <0,005). En el análisis multivariante, los no progresores tuvieron resultados comparables a los progresores (p=0,76), pero significativamente peores que los respondedores (HR=4,01).

Conclusiones

En nuestra población, los no progresores mostraron resultados similares a los no respondedores, lo que subraya el papel del remodelado positivo más allá de la estabilización y la necesidad de optimizar la evaluación de la respuesta ecocardiográfica a la TRC.

Palabras clave:
Terapia de resincronización cardiaca
Insuficiencia cardiaca
Estabilización
No progresión

Article

These are the options to access the full texts of the publication REC: CardioClinics
Member
Socios SEC
Use datos de acceso a SEC en el menú Acceder.
Si es socio de la Sociedad Española de Cardiología y no puede acceder con sus claves, escriba a rec@cardioclinics.org.
Members of SEC
Use the Society's website login and password here.
If you are member of SEC and you have some problems with your login data, please contact with rec@cardioclinics.org.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
REC: CardioClinics
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
References
[1]
T.A. Abe, E.O. Evbayekha, L.R. Jackson II, et al.
Evolving indications, challenges and advances in cardiac resynchronization therapy for heart failure.
[2]
B.J. Sieniewicz, J. Gould, B. Porter, et al.
Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions.
Heart Fail Rev, 24 (2019), pp. 41-54
[3]
I.S. Anand, P. Carson, E. Galle, et al.
Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure results from the comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial.
Circulation, (2009), pp. 969-977
[4]
C. Linde, W.T. Abraham, M.R. Gold, et al.
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
J Am Coll Cardiol, 52 (2008), pp. 1834-1843
[5]
M. Glikson, J.C. Nielsen, C. Leclercq, et al.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
Eur Heart J, 42 (2021), pp. 3427-3520
[6]
L. Gerra, N. Bonini, D.A. Mei, et al.
Cardiac resynchronization therapy (CRT) nonresponders in the contemporary era: a state-of-the-art review.
Hear Rhythm, 22 (2025), pp. 159-169
[7]
M.R. Gold, J. Rickard, J.C. Daubert, et al.
Redefining the classifications of response to cardiac resynchronization therapy: results from the REVERSE Study.
JACC Clin Electrophysiol, 7 (2021), pp. 871-880
[8]
J. Cleland, N. Freemantle, S. Ghio, et al.
Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response: a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
J Am Coll Cardiol, 52 (2008), pp. 438-445
[9]
E.C. Adelstein, S. Saba.
Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy.
Am Heart J, 153 (2007), pp. 105-112
[10]
S.H. Kang, I.Y. Oh, D.Y. Kang, et al.
Cardiac resynchronization therapy and QRS duration: systematic review, meta-analysis, and meta-regression.
J Korean Med Sci, 30 (2015), pp. 24-33
[11]
C. Cunnington, C.S. Kwok, D.K. Satchithananda, et al.
Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials.
Heart, 101 (2015), pp. 1456-1462
[12]
L.E. Sade, B. Özin, I. Atar, et al.
Right ventricular function is a determinant of long-term survival after cardiac resynchronization therapy.
J Am Soc Echocardiogr, 26 (2013), pp. 706-713
[13]
W. Mullens, A. Auricchio, P. Martens, et al.
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association.
Eur J Heart Fail, 22 (2020), pp. 2349-2369
[14]
M. St John Sutton, C. Linde, M.R. Gold, et al.
Left ventricular architecture long-term reverse remodeling, and clinical outcome in mild heart failure with cardiac resynchronization: results from the REVERSE Trial.
JACC Heart Fail, 5 (2017), pp. 169-178
[15]
C. Daubert, C. Linde.
Cardiac resynchronization therapy: new perspectives.
Circulation, 150 (2024), pp. 1563-1566
[16]
W. Mullens, T. Verga, R.A. Grimm, et al.
Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure.
J Am Coll Cardiol, 53 (2009), pp. 600-607
[17]
E.S. Chung, M.R. Gold, W.T. Abraham, et al.
The importance of early evaluation after cardiac resynchronization therapy to redefine response: pooled individual patient analysis from 5 prospective studies.
Hear Rhythm, 19 (2022), pp. 595-603
[18]
S. Trenson, P.C. Kahr, B. Vandenberk, et al.
Long-term nonprogression is a form of response to cardiac resynchronization therapy.
[19]
M. Packer.
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure.
J Card Fail, 7 (2001), pp. 176-182
[20]
A.Z. Toth, L. Nagy, K.M. Szabo, et al.
Early occurrence of heart failure hospitalization or ventricular arrhythmia re-define the long-term prognosis after CRT.
ESC Hear Fail, 12 (2025), pp. 2780-2790
[21]
P. Rio, M.M. Oliveira, P.S. Cunha, et al.
What happens to non-responders in cardiac resynchronization therapy?.
Rev Port Cardiol, 36 (2017), pp. 885-892
[22]
F.J. Pastor-Pérez, I.P. Garrido-Bravo, P. Peñafiel-Verdú, et al.
Withdrawal of drug therapy in responders to cardiac resynchronization therapy; rationale and design of the REMOVE trial.
Rev Esp Cardiol, 77 (2024), pp. 805-878
[23]
A.J. Moss, W. Jackson Hall, D.S. Cannom, et al.
Cardiac-resynchronization therapy for the prevention of heart-failure events.
N Engl J Med, 361 (2009), pp. 1329-1338
[24]
J. Rickard, M.R. Gold, D. Patel, et al.
Long-term outcomes in nonprogressors to cardiac resynchronization therapy.
Hear Rhythm, 20 (2022), pp. 165-170
[25]
X. Chen, Q. Jin, Z. Qiu, et al.
Outcomes of upgrading to LBBP in CRT nonresponders: a prospective, multicenter, nonrandomized, case–control study.
JACC Clin Electrophysiol, 10 (2024), pp. 108-120
Idiomas
REC: CardioClinics
Article options
Tools